{
  "collected_at_utc": "2026-03-02T05:39:59.388874+00:00",
  "files_found": [
    "validation_results.json",
    "calibration_results.json",
    "statistical_results.json",
    "fn_analysis.json",
    "repodb_paper.json",
    "pbc_predictions.json"
  ],
  "files_missing": [],
  "curated_validation": {
    "dataset_version": "v4.0",
    "n_cases": 55,
    "n_positive": 25,
    "n_negative": 30,
    "pass_criterion": "rank_ok OR score_ok (v3.1)",
    "elapsed_seconds": 10811.84,
    "metrics": {
      "tp": 24,
      "fn": 1,
      "tn": 29,
      "fp": 1,
      "sensitivity": 0.96,
      "specificity": 0.9667,
      "precision": 0.96,
      "f1": 0.96,
      "rank_only_passes": 1,
      "score_only_passes": 1,
      "both_criteria_passes": 22
    },
    "stratified_metrics": {
      "cardiovascular": {
        "tp": 2,
        "fn": 0,
        "tn": 0,
        "fp": 0,
        "sensitivity": 1.0,
        "specificity": null,
        "n_positive_cases": 2,
        "n_negative_cases": 0
      },
      "metabolic": {
        "tp": 3,
        "fn": 0,
        "tn": 2,
        "fp": 0,
        "sensitivity": 1.0,
        "specificity": 1.0,
        "n_positive_cases": 3,
        "n_negative_cases": 2
      },
      "oncology": {
        "tp": 9,
        "fn": 0,
        "tn": 7,
        "fp": 0,
        "sensitivity": 1.0,
        "specificity": 1.0,
        "n_positive_cases": 9,
        "n_negative_cases": 7
      },
      "autoimmune_inflammatory": {
        "tp": 3,
        "fn": 0,
        "tn": 5,
        "fp": 0,
        "sensitivity": 1.0,
        "specificity": 1.0,
        "n_positive_cases": 3,
        "n_negative_cases": 5
      },
      "neurological": {
        "tp": 1,
        "fn": 0,
        "tn": 12,
        "fp": 0,
        "sensitivity": 1.0,
        "specificity": 1.0,
        "n_positive_cases": 1,
        "n_negative_cases": 12
      },
      "rare_disease": {
        "tp": 5,
        "fn": 1,
        "tn": 2,
        "fp": 0,
        "sensitivity": 0.8333,
        "specificity": 1.0,
        "n_positive_cases": 6,
        "n_negative_cases": 2
      },
      "other": {
        "tp": 1,
        "fn": 0,
        "tn": 1,
        "fp": 1,
        "sensitivity": 1.0,
        "specificity": 0.5,
        "n_positive_cases": 1,
        "n_negative_cases": 2
      }
    },
    "baseline_comparison": {
      "top_k": 100,
      "baselines": {
        "jaccard": {
          "sensitivity": 0.72,
          "specificity": 0.9,
          "precision": 0.8571,
          "f1": 0.7826,
          "tp": 18,
          "fn": 7,
          "tn": 27,
          "fp": 3
        },
        "gene_count": {
          "sensitivity": 0.76,
          "specificity": 0.9,
          "precision": 0.8636,
          "f1": 0.8085,
          "tp": 19,
          "fn": 6,
          "tn": 27,
          "fp": 3
        },
        "cosine": {
          "sensitivity": 0.72,
          "specificity": 0.9667,
          "precision": 0.9474,
          "f1": 0.8182,
          "tp": 18,
          "fn": 7,
          "tn": 29,
          "fp": 1
        }
      }
    },
    "baseline_f1_delta": {
      "jaccard": {
        "main_f1": 0.96,
        "baseline_f1": 0.7826,
        "f1_delta": 0.1774,
        "main_better": true
      },
      "gene_count": {
        "main_f1": 0.96,
        "baseline_f1": 0.8085,
        "f1_delta": 0.1515,
        "main_better": true
      },
      "cosine": {
        "main_f1": 0.96,
        "baseline_f1": 0.8182,
        "f1_delta": 0.1418,
        "main_better": true
      }
    },
    "sensitivity_analysis": {
      "rank_correlation_min": 0.9578,
      "rank_correlation_max": 1.0,
      "rank_correlation_mean": 0.9952,
      "stable": true,
      "perturbation_results": [
        {
          "perturbed": "gene",
          "direction": "+",
          "spearman_r": 0.9988
        },
        {
          "perturbed": "gene",
          "direction": "-",
          "spearman_r": 0.9979
        },
        {
          "perturbed": "pathway",
          "direction": "+",
          "spearman_r": 0.999
        },
        {
          "perturbed": "pathway",
          "direction": "-",
          "spearman_r": 0.9991
        },
        {
          "perturbed": "ppi",
          "direction": "+",
          "spearman_r": 0.9994
        },
        {
          "perturbed": "ppi",
          "direction": "-",
          "spearman_r": 0.999
        },
        {
          "perturbed": "similarity",
          "direction": "+",
          "spearman_r": 0.9915
        },
        {
          "perturbed": "similarity",
          "direction": "-",
          "spearman_r": 0.9578
        },
        {
          "perturbed": "mechanism",
          "direction": "+",
          "spearman_r": 1.0
        },
        {
          "perturbed": "mechanism",
          "direction": "-",
          "spearman_r": 1.0
        },
        {
          "perturbed": "literature",
          "direction": "+",
          "spearman_r": 1.0
        },
        {
          "perturbed": "literature",
          "direction": "-",
          "spearman_r": 1.0
        }
      ],
      "paper_statement": "Sensitivity analysis: Spearman \u03c1 range [0.958, 1.000], mean=0.995 across \u00b110% weight perturbations. Rankings are stable (\u03c1_min \u2265 0.90)."
    },
    "data_integrity": {
      "passed": true,
      "n_drugs": 3002,
      "target_coverage": 0.7945,
      "issues": [],
      "warnings": []
    },
    "pipeline_fingerprint": {
      "dataset_version": "v4.0",
      "run_timestamp_utc": "2026-02-24T20:52:52.336128+00:00",
      "n_drugs_in_pool": 3002,
      "target_source_breakdown": {
        "dgidb": 2064,
        "chembl_mechanism": 264,
        "none": 617,
        "opentargets_drug": 57
      },
      "scoring_weights": {
        "gene": 0.35,
        "pathway": 0.25,
        "ppi": 0.2,
        "similarity": 0.1,
        "mechanism": 0.05,
        "literature": 0.05
      },
      "data_sources": [
        "ChEMBL (max_phase=4)",
        "OpenTargets Platform",
        "DGIdb 4.0",
        "STRING v12 (PPI)",
        "Reactome v88",
        "KEGG PATHWAY"
      ]
    },
    "positive_results": [
      {
        "drug": "sildenafil",
        "disease": "pulmonary arterial hypertension",
        "disease_area": "cardiovascular",
        "pass": true,
        "raw_score": 0.4563,
        "calibrated_score": 0.4702,
        "rank": 12,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "PDE5 inhibition \u2192 cGMP elevation \u2192 vasodilation; shared VEGF/NO pathway genes",
        "notes": "FDA-approved for PAH.",
        "score_components": {
          "gene_score": 0.024592381345109233,
          "pathway_score": 0.3813559322033898,
          "ppi_score": 0.3529,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "NOS3",
            "VEGFA",
            "PDE5A"
          ],
          "shared_pathways": [
            "Nitric oxide signaling",
            "cGMP-PKG signaling",
            "Pulmonary vascular remodeling"
          ]
        }
      },
      {
        "drug": "metformin",
        "disease": "type 2 diabetes mellitus",
        "disease_area": "metabolic",
        "pass": true,
        "raw_score": 0.4169,
        "calibrated_score": 0.4704,
        "rank": 2,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "AMPK activation \u2192 glucose uptake; primary indication",
        "notes": "Primary indication. Used as positive control.",
        "score_components": {
          "gene_score": 0.22235266820969937,
          "pathway_score": 0.0,
          "ppi_score": 0.3906,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "HNF1B",
            "PPARA",
            "SLC22A3",
            "KCNJ11",
            "BDNF",
            "PPARG",
            "SLC2A2",
            "TCF7L2"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "metformin",
        "disease": "polycystic ovary syndrome",
        "disease_area": "metabolic",
        "pass": true,
        "raw_score": 0.1425,
        "calibrated_score": 0.4722,
        "rank": 197,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "Insulin sensitisation; shared INSR/AMPK pathway genes",
        "notes": "Off-label use supported by RCTs.",
        "score_components": {
          "gene_score": 0.01294421336433204,
          "pathway_score": 0.0,
          "ppi_score": 0.3396,
          "similarity_score": 0.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "PPARG",
            "PTEN"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "thalidomide",
        "disease": "multiple myeloma",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.6706,
        "calibrated_score": 0.4687,
        "rank": 2,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "Anti-angiogenic; TNF-alpha suppression; shared VEGF/IKZF pathway",
        "notes": "",
        "score_components": {
          "gene_score": 0.14256216490086962,
          "pathway_score": 1.0,
          "ppi_score": 0.4175,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "PTGS2",
            "FGFR2",
            "HGF",
            "DDB1",
            "CUL4A",
            "RBX1",
            "CRBN"
          ],
          "shared_pathways": [
            "Ubiquitin-proteasome system",
            "Protein degradation"
          ]
        }
      },
      {
        "drug": "imatinib",
        "disease": "chronic myelogenous leukemia",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.9115,
        "calibrated_score": 0.4672,
        "rank": 1,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "BCR-ABL1 kinase inhibition; primary indication",
        "notes": "",
        "score_components": {
          "gene_score": 0.43597101840146907,
          "pathway_score": 1.0,
          "ppi_score": 0.495,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "ABL1",
            "CSF3R",
            "FRK",
            "YES1",
            "PRKCH",
            "MYC",
            "RUNX1",
            "EGFR",
            "CSF1R",
            "NF1",
            "HCK",
            "PDGFRB",
            "BRAF",
            "JAK2",
            "CTNNB1",
            "BCR",
            "PTEN",
            "IDH1",
            "LCK",
            "KIT",
            "FLT3",
            "KRAS",
            "IKZF1",
            "LYN"
          ],
          "shared_pathways": [
            "PDGFR signaling",
            "Pulmonary vascular remodeling",
            "BCR-ABL signaling",
            "Tyrosine kinase signaling"
          ]
        }
      },
      {
        "drug": "imatinib",
        "disease": "gastrointestinal stromal tumor",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.6619,
        "calibrated_score": 0.4688,
        "rank": 4,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "KIT/PDGFRA inhibition; shared kinase pathway with CML",
        "notes": "",
        "score_components": {
          "gene_score": 0.36143880975204723,
          "pathway_score": 0.4417808219178082,
          "ppi_score": 0.4975,
          "similarity_score": 0.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "ABL1",
            "FRK",
            "ALK",
            "HGF",
            "NF2",
            "EGFR",
            "CSF1R",
            "NF1",
            "PDGFRB",
            "RET",
            "BRAF",
            "BCR",
            "NTRK1",
            "PTEN",
            "PDGFRA",
            "KIT",
            "FLT3",
            "KRAS",
            "IKZF1"
          ],
          "shared_pathways": [
            "PDGFR signaling",
            "Receptor tyrosine kinase",
            "BCR-ABL signaling",
            "Pulmonary vascular remodeling",
            "Tyrosine kinase signaling"
          ]
        }
      },
      {
        "drug": "letrozole",
        "disease": "breast cancer",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.6699,
        "calibrated_score": 0.4688,
        "rank": 5,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "Aromatase (CYP19A1) inhibition \u2192 estrogen reduction",
        "notes": "",
        "score_components": {
          "gene_score": 0.22994070968266,
          "pathway_score": 0.375,
          "ppi_score": 0.4405,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "RB1",
            "CDKN2A",
            "CYP19A1",
            "ERBB2",
            "PTEN",
            "KIT",
            "ESR1",
            "PIK3CA"
          ],
          "shared_pathways": [
            "Nuclear receptor signaling",
            "EGFR signaling",
            "HER2 signaling",
            "Estrogen receptor signaling"
          ]
        }
      },
      {
        "drug": "olaparib",
        "disease": "ovarian cancer",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.7824,
        "calibrated_score": 0.468,
        "rank": 1,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "PARP1/2 inhibition \u2192 synthetic lethality in BRCA1/2-mutant cells",
        "notes": "",
        "score_components": {
          "gene_score": 0.7129956247016708,
          "pathway_score": 0.22285714285714286,
          "ppi_score": 0.5102,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "RAD51B",
            "TET2",
            "CDK12",
            "PARP1",
            "PARP3",
            "RAD51C",
            "ATM",
            "BRCA2",
            "ATRX",
            "CHEK2",
            "MYC",
            "BRCA1",
            "BARD1",
            "BRAF",
            "ARID1B",
            "ATR",
            "DNMT3A",
            "FANCA",
            "ESR1",
            "PIK3CA",
            "RB1",
            "PALB2",
            "ERBB2",
            "RAD51D",
            "PTEN",
            "PARP2",
            "TP53"
          ],
          "shared_pathways": [
            "Nuclear receptor signaling",
            "Estrogen receptor signaling"
          ]
        }
      },
      {
        "drug": "nivolumab",
        "disease": "non-small cell lung carcinoma",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.6411,
        "calibrated_score": 0.4689,
        "rank": 4,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "PD-1 checkpoint blockade; shared PDCD1/CD274 pathway",
        "notes": "",
        "score_components": {
          "gene_score": 0.49064917129734864,
          "pathway_score": 0.34285714285714286,
          "ppi_score": 0.4866,
          "similarity_score": 0.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "CDK12",
            "STK11",
            "ALK",
            "NRAS",
            "ATM",
            "ARID1A",
            "PDCD1",
            "EGFR",
            "MSH6",
            "CD274",
            "BRAF",
            "PBRM1",
            "PIK3CA",
            "FGFR3",
            "ERBB2",
            "MLH1",
            "PTEN",
            "KRAS",
            "TP53"
          ],
          "shared_pathways": [
            "EGFR signaling",
            "HER2 signaling",
            "MAPK signaling"
          ]
        }
      },
      {
        "drug": "pembrolizumab",
        "disease": "melanoma",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.4842,
        "calibrated_score": 0.47,
        "rank": 21,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "PD-1 checkpoint blockade; shared PDCD1/CD274/TMB pathway",
        "notes": "",
        "score_components": {
          "gene_score": 0.5138857823560713,
          "pathway_score": 0.0,
          "ppi_score": 0.5038,
          "similarity_score": 0.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "POLE",
            "ROS1",
            "CDK12",
            "STK11",
            "B2M",
            "NRAS",
            "ARID1A",
            "PDCD1",
            "MDM2",
            "MET",
            "CD274",
            "BRAF",
            "PBRM1",
            "ERBB2",
            "FGFR1",
            "PTEN",
            "IDH1",
            "KIT",
            "TP53",
            "MDM4"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "aspirin",
        "disease": "colorectal cancer",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.2982,
        "calibrated_score": 0.4712,
        "rank": 65,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "COX-2/PTGS2 inhibition \u2192 prostaglandin reduction \u2192 anti-proliferative",
        "notes": "",
        "score_components": {
          "gene_score": 0.0946298071397681,
          "pathway_score": 0.0,
          "ppi_score": 0.4255,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "NTRK1",
            "PPARG",
            "PIK3CA",
            "TSC1"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "rituximab",
        "disease": "rheumatoid arthritis",
        "disease_area": "autoimmune_inflammatory",
        "pass": true,
        "raw_score": 0.4279,
        "calibrated_score": 0.4704,
        "rank": 2,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "CD20+ B-cell depletion; shared inflammatory pathway genes",
        "notes": "",
        "score_components": {
          "gene_score": 0.09663193178462118,
          "pathway_score": 0.2011173184357542,
          "ppi_score": 0.3854,
          "similarity_score": 0.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "IL6",
            "FCGR2A",
            "CXCL13",
            "JAK2",
            "MS4A1"
          ],
          "shared_pathways": [
            "JAK-STAT signaling",
            "B-cell receptor signaling",
            "B-cell differentiation"
          ]
        }
      },
      {
        "drug": "hydroxychloroquine",
        "disease": "systemic lupus erythematosus",
        "disease_area": "autoimmune_inflammatory",
        "pass": true,
        "raw_score": 0.269,
        "calibrated_score": 0.4714,
        "rank": 1,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "TLR9 inhibition, autophagy modulation; shared interferonopathy pathway",
        "notes": "",
        "score_components": {
          "gene_score": 0.04296813291971492,
          "pathway_score": 0.0,
          "ppi_score": 0.3436,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "PTGS2",
            "TLR7",
            "TLR9"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "gabapentin",
        "disease": "epilepsy",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.3939,
        "calibrated_score": 0.4706,
        "rank": 45,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "CACNA2D1 subunit inhibition \u2192 reduced calcium influx",
        "notes": "",
        "score_components": {
          "gene_score": 0.2559463103200942,
          "pathway_score": 0.0,
          "ppi_score": 0.3578,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "CACNA2D1",
            "CACNA1B",
            "CACNA1A",
            "CACNA1I",
            "CACNA2D2",
            "CACNA1H",
            "KCNQ3",
            "CACNA1G",
            "CACNA1E"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "finasteride",
        "disease": "benign prostatic hyperplasia",
        "disease_area": "rare_disease",
        "pass": true,
        "raw_score": 0.4534,
        "calibrated_score": 0.4702,
        "rank": 2,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "5-alpha-reductase inhibition; shared SRD5A1/SRD5A2 pathway",
        "notes": "",
        "score_components": {
          "gene_score": 0.04598029796568254,
          "pathway_score": 0.24715909090909088,
          "ppi_score": 0.2909,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "SRD5A2",
            "SRD5A1",
            "AR"
          ],
          "shared_pathways": [
            "Androgen receptor signaling",
            "Hair follicle cycling",
            "5-alpha reductase pathway"
          ]
        }
      },
      {
        "drug": "colchicine",
        "disease": "gout",
        "disease_area": "other",
        "pass": true,
        "raw_score": 0.422,
        "calibrated_score": 0.4704,
        "rank": 2,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "Microtubule polymerisation inhibition; primary indication",
        "notes": "",
        "score_components": {
          "gene_score": 0.24907973903199443,
          "pathway_score": 0.0,
          "ppi_score": 0.3425,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "TUBB2A",
            "TUBB6",
            "NRG1",
            "TUBB1",
            "TUBB4B",
            "BDNF",
            "TUBB",
            "TUBB8",
            "TUBB4A",
            "TUBB3",
            "TUBB2B"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "colchicine",
        "disease": "pericarditis",
        "disease_area": "autoimmune_inflammatory",
        "pass": true,
        "raw_score": 0.3461,
        "calibrated_score": 0.4709,
        "rank": 1,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "NLRP3 inflammasome inhibition; shared IL1B pathway genes",
        "notes": "",
        "score_components": {
          "gene_score": 0.13527845695926147,
          "pathway_score": 0.0,
          "ppi_score": 0.3119,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "TUBB2A",
            "TUBB6",
            "TUBB1",
            "TUBB4B",
            "TUB",
            "TUBB",
            "TUBB8",
            "TUBB4A",
            "TUBB3",
            "TUBB2B"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "lenalidomide",
        "disease": "multiple myeloma",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.7042,
        "calibrated_score": 0.4685,
        "rank": 1,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "IKZF1/IKZF3 degradation via CRBN; immunomodulatory",
        "notes": "",
        "score_components": {
          "gene_score": 0.1405120880234029,
          "pathway_score": 1.0,
          "ppi_score": 0.4405,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "DDB1",
            "CUL4A",
            "KDR",
            "RBX1",
            "TP53",
            "CRBN"
          ],
          "shared_pathways": [
            "Ubiquitin-proteasome system",
            "Protein degradation"
          ]
        }
      },
      {
        "drug": "propranolol",
        "disease": "infantile hemangioma",
        "disease_area": "rare_disease",
        "pass": true,
        "raw_score": 0.0656,
        "calibrated_score": 0.4727,
        "rank": 1352,
        "rank_pass": false,
        "score_pass": true,
        "status": "found",
        "mechanism": "Beta-adrenergic blockade \u2192 anti-angiogenic; VEGF pathway shared",
        "notes": "Known FN pattern: drug_not_found in standard scoring.",
        "score_components": {
          "gene_score": 0.0,
          "pathway_score": 0.0,
          "ppi_score": 0.3279,
          "similarity_score": 0.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [],
          "shared_pathways": []
        }
      },
      {
        "drug": "sirolimus",
        "disease": "tuberous sclerosis",
        "disease_area": "rare_disease",
        "pass": true,
        "raw_score": 0.304,
        "calibrated_score": 0.4712,
        "rank": 51,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "mTOR pathway inhibition; TSC1/TSC2 direct targets",
        "notes": "",
        "score_components": {
          "gene_score": 0.12524418074632013,
          "pathway_score": 0.0,
          "ppi_score": 0.3506,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "FKBP1A",
            "TSC2",
            "TSC1"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "eculizumab",
        "disease": "paroxysmal nocturnal hemoglobinuria",
        "disease_area": "rare_disease",
        "pass": true,
        "raw_score": 0.1581,
        "calibrated_score": 0.4721,
        "rank": 2,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "C5 complement inhibition; shared complement pathway genes",
        "notes": "",
        "score_components": {
          "gene_score": 0.07989944371417271,
          "pathway_score": 0.0,
          "ppi_score": 0.375,
          "similarity_score": 0.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "C5"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "ivacaftor",
        "disease": "cystic fibrosis",
        "disease_area": "rare_disease",
        "pass": true,
        "raw_score": 0.3421,
        "calibrated_score": 0.4709,
        "rank": 2,
        "rank_pass": true,
        "score_pass": false,
        "status": "found",
        "mechanism": "CFTR potentiation; direct CFTR shared gene",
        "notes": "",
        "score_components": {
          "gene_score": 0.04101299032173717,
          "pathway_score": 0.05,
          "ppi_score": 0.3517,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "SLC26A9",
            "CFTR"
          ],
          "shared_pathways": [
            "Chloride ion transport"
          ]
        }
      },
      {
        "drug": "nusinersen",
        "disease": "spinal muscular atrophy",
        "disease_area": "rare_disease",
        "pass": false,
        "raw_score": 0.0,
        "calibrated_score": 0.4732,
        "rank": null,
        "rank_pass": false,
        "score_pass": false,
        "status": "false_negative",
        "mechanism": "Antisense oligonucleotide promoting SMN2 exon 7 inclusion",
        "notes": "KNOWN LIMITATION: max_phase=3, not in ChEMBL approved pool. drug_not_found expected. Case documents ASO coverage gap.",
        "score_components": {}
      },
      {
        "drug": "ezetimibe",
        "disease": "hypercholesterolemia",
        "disease_area": "metabolic",
        "pass": true,
        "raw_score": 0.2058,
        "calibrated_score": 0.4718,
        "rank": 33,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "NPC1L1 inhibition \u2192 reduced cholesterol absorption",
        "notes": "",
        "score_components": {
          "gene_score": 0.01739285553245915,
          "pathway_score": 0.0,
          "ppi_score": 0.2903,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "NPC1L1"
          ],
          "shared_pathways": []
        }
      },
      {
        "drug": "empagliflozin",
        "disease": "heart failure",
        "disease_area": "cardiovascular",
        "pass": true,
        "raw_score": 0.1849,
        "calibrated_score": 0.472,
        "rank": 191,
        "rank_pass": true,
        "score_pass": true,
        "status": "found",
        "mechanism": "SGLT2 inhibition \u2192 diuresis, cardiac preload reduction",
        "notes": "",
        "score_components": {
          "gene_score": 0.014957282592188455,
          "pathway_score": 0.0,
          "ppi_score": 0.2981,
          "similarity_score": 1.0,
          "mechanism_score": 0.0,
          "literature_score": 0.0,
          "shared_genes": [
            "SLC5A2"
          ],
          "shared_pathways": []
        }
      }
    ],
    "negative_results": [
      {
        "drug": "insulin glargine",
        "disease": "multiple sclerosis",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0581,
        "status": "true_negative_low_score"
      },
      {
        "drug": "warfarin",
        "disease": "Parkinson disease",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0945,
        "status": "true_negative_low_score"
      },
      {
        "drug": "omeprazole",
        "disease": "schizophrenia",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0642,
        "status": "true_negative_low_score"
      },
      {
        "drug": "atorvastatin",
        "disease": "hemophilia A",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.0,
        "status": "true_negative_low_score"
      },
      {
        "drug": "lisinopril",
        "disease": "anorexia nervosa",
        "disease_area": "other",
        "pass": true,
        "raw_score": 0.0553,
        "status": "true_negative_low_score"
      },
      {
        "drug": "levothyroxine",
        "disease": "inflammatory bowel disease",
        "disease_area": "autoimmune_inflammatory",
        "pass": true,
        "raw_score": 0.1919,
        "status": "true_negative_low_score"
      },
      {
        "drug": "amoxicillin",
        "disease": "hypertrophic cardiomyopathy",
        "disease_area": "autoimmune_inflammatory",
        "pass": true,
        "raw_score": 0.03,
        "status": "true_negative_low_score"
      },
      {
        "drug": "donepezil",
        "disease": "amyotrophic lateral sclerosis",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0856,
        "status": "true_negative_low_score"
      },
      {
        "drug": "fluconazole",
        "disease": "Alzheimer disease",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0699,
        "status": "true_negative_low_score"
      },
      {
        "drug": "ciprofloxacin",
        "disease": "multiple myeloma",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.0667,
        "status": "true_negative_low_score"
      },
      {
        "drug": "metronidazole",
        "disease": "Parkinson disease",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0648,
        "status": "true_negative_low_score"
      },
      {
        "drug": "azithromycin",
        "disease": "breast cancer",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.0,
        "status": "true_negative_low_score"
      },
      {
        "drug": "glipizide",
        "disease": "rheumatoid arthritis",
        "disease_area": "autoimmune_inflammatory",
        "pass": true,
        "raw_score": 0.061,
        "status": "true_negative_low_score"
      },
      {
        "drug": "sitagliptin",
        "disease": "epilepsy",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0608,
        "status": "true_negative_low_score"
      },
      {
        "drug": "canagliflozin",
        "disease": "ovarian cancer",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.0,
        "status": "true_negative_not_found"
      },
      {
        "drug": "pioglitazone",
        "disease": "schizophrenia",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0586,
        "status": "true_negative_low_score"
      },
      {
        "drug": "amlodipine",
        "disease": "multiple myeloma",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.0602,
        "status": "true_negative_low_score"
      },
      {
        "drug": "digoxin",
        "disease": "cystic fibrosis",
        "disease_area": "rare_disease",
        "pass": true,
        "raw_score": 0.1483,
        "status": "true_negative_low_score"
      },
      {
        "drug": "clopidogrel",
        "disease": "Alzheimer disease",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0908,
        "status": "true_negative_low_score"
      },
      {
        "drug": "furosemide",
        "disease": "rheumatoid arthritis",
        "disease_area": "autoimmune_inflammatory",
        "pass": true,
        "raw_score": 0.0684,
        "status": "true_negative_low_score"
      },
      {
        "drug": "sertraline",
        "disease": "epilepsy",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0,
        "status": "true_negative_low_score"
      },
      {
        "drug": "lithium",
        "disease": "cystic fibrosis",
        "disease_area": "rare_disease",
        "pass": true,
        "raw_score": 0.0,
        "status": "true_negative_not_found"
      },
      {
        "drug": "zolpidem",
        "disease": "inflammatory bowel disease",
        "disease_area": "autoimmune_inflammatory",
        "pass": true,
        "raw_score": 0.0,
        "status": "true_negative_low_score"
      },
      {
        "drug": "aripiprazole",
        "disease": "type 2 diabetes mellitus",
        "disease_area": "metabolic",
        "pass": true,
        "raw_score": 0.0873,
        "status": "true_negative_low_score"
      },
      {
        "drug": "tacrolimus",
        "disease": "chronic myelogenous leukemia",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.0,
        "status": "true_negative_not_found"
      },
      {
        "drug": "allopurinol",
        "disease": "multiple sclerosis",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.0643,
        "status": "true_negative_low_score"
      },
      {
        "drug": "etoposide",
        "disease": "Parkinson disease",
        "disease_area": "neurological",
        "pass": true,
        "raw_score": 0.1841,
        "status": "true_negative_low_score"
      },
      {
        "drug": "cyclosporine",
        "disease": "gout",
        "disease_area": "other",
        "pass": false,
        "raw_score": 0.2477,
        "status": "false_positive"
      },
      {
        "drug": "heparin",
        "disease": "breast cancer",
        "disease_area": "oncology",
        "pass": true,
        "raw_score": 0.0,
        "status": "true_negative_not_found"
      },
      {
        "drug": "montelukast",
        "disease": "type 2 diabetes mellitus",
        "disease_area": "metabolic",
        "pass": true,
        "raw_score": 0.0531,
        "status": "true_negative_low_score"
      }
    ]
  },
  "calibration": {
    "platt_A": -0.0266,
    "platt_B": -0.1076,
    "platt_source": "fitted_from_validation_data",
    "ece": 0.0188,
    "ece_status": "excellent",
    "ece_paper_note": "Calibration is excellent (ECE < 0.10).",
    "calibrated_scores_usable": true,
    "raw_threshold_at_50pct": -4.0521,
    "practical_raw_threshold": 0.2,
    "effect_sizes": {
      "cohens_d_tp_vs_fn": null,
      "cohens_d_tp_vs_fp": null,
      "cohens_d_note": "Cohen's d is None when group n < 5. fp_scores typically n=0-2; effect size vs FP unreliable."
    },
    "score_distributions": {
      "tp": {
        "n": 24,
        "mean": 0.4339,
        "sd": 0.2211,
        "min": 0.0656,
        "max": 0.9115
      },
      "fn": {
        "n": 1,
        "mean": 0.0,
        "sd": 0.0,
        "min": 0.0,
        "max": 0.0,
        "note": "FN excluded from Platt fitting (known positives, model failure)."
      },
      "tn": {
        "n": 29,
        "mean": 0.0592,
        "sd": 0.0515,
        "min": 0.0,
        "max": 0.1919
      },
      "fp": {
        "n": 1,
        "mean": 0.2477,
        "sd": 0.0,
        "min": 0.2477,
        "max": 0.2477,
        "note": "FP typically n=0-2; Cohen's d vs TP unreliable."
      }
    },
    "paper_reporting_note": "Raw network overlap scores were calibrated using Platt scaling (A = -0.027, B = -0.108; fitted by gradient-descent maximum-likelihood logistic regression on 53 binary-certain validation cases). ECE = 0.0188. Calibrated probabilities are reported for supplementary ranking only. Primary performance metrics use sensitivity, specificity, precision, and rank-based retrieval, with binary classification threshold raw_score \u2265 0.2."
  },
  "statistical_tests": {
    "bootstrap_ci": {
      "sensitivity": {
        "point_estimate": 0.96,
        "ci_lower": 0.88,
        "ci_upper": 1.0,
        "se": 0.0384,
        "n_bootstrap": 1000,
        "alpha": 0.05,
        "ci_label": "95% CI"
      },
      "specificity": {
        "point_estimate": 0.9667,
        "ci_lower": 0.9,
        "ci_upper": 1.0,
        "se": 0.0323,
        "n_bootstrap": 1000,
        "alpha": 0.05,
        "ci_label": "95% CI"
      },
      "precision": {
        "point_estimate": 0.96,
        "ci_lower": 0.8846,
        "ci_upper": 1.0,
        "se": 0.0363,
        "n_bootstrap": 1000,
        "alpha": 0.05,
        "ci_label": "95% CI"
      },
      "f1": {
        "point_estimate": 0.96,
        "ci_lower": 0.898,
        "ci_upper": 1.0,
        "se": 0.0275,
        "n_bootstrap": 1000,
        "alpha": 0.05,
        "ci_label": "95% CI"
      }
    },
    "mcnemar_test": {
      "skipped": true,
      "reason": "No 'baseline_pass' key in validation_results.json"
    },
    "delong_test": {
      "skipped": true,
      "reason": "No 'baseline_score' key in validation_results.json"
    },
    "paper_summary": {
      "ready_to_paste_lines": [
        "Sensitivity = 0.960 (95% CI: 0.880\u20131.000)",
        "Specificity = 0.967 (95% CI: 0.900\u20131.000)",
        "Precision = 0.960 (95% CI: 0.885\u20131.000)",
        "F1 = 0.960 (95% CI: 0.898\u20131.000)"
      ],
      "methods_blurb": "Bootstrap 95% confidence intervals were computed using 1000 stratified resampling iterations (seed=42). McNemar's test (two-sided, \u03b1=0.05) compared algorithm and Jaccard baseline on paired binary predictions. AUC-ROC values were compared using DeLong's test (DeLong et al. 1988)."
    },
    "metadata": {
      "input_file": "validation_results.json",
      "n_positive_cases": 25,
      "n_negative_cases": 30,
      "n_bootstrap_iters": 1000,
      "bootstrap_seed": 42
    }
  },
  "fn_analysis": {
    "summary": {
      "n_positive_cases": 25,
      "n_false_negatives": 1,
      "fn_rate": 0.04,
      "fn_rate_percent": 4.0,
      "category_breakdown": {
        "drug_not_found": 1
      }
    },
    "false_negative_cases": [
      {
        "drug": "nusinersen",
        "disease": "spinal muscular atrophy",
        "raw_score": 0.0,
        "rank": null,
        "min_score_expected": 0.0,
        "category": "drug_not_found",
        "remediation": "Drug not in candidate list at all. Likely causes: (1) Drug name in validation_dataset.py does not match ChEMBL preferred name. (2) Drug has no targets from DGIdb or fallback. (3) Drug filtered out before scoring. Check: data_fetcher.py logs for this drug name.",
        "mechanism": "Antisense oligonucleotide promoting SMN2 exon 7 inclusion",
        "sources": [
          "PMID:28056917"
        ],
        "notes": "KNOWN LIMITATION: max_phase=3, not in ChEMBL approved pool. drug_not_found expected. Case documents ASO coverage gap."
      }
    ]
  },
  "repodb_benchmark": {
    "source_file": "repodb_paper.json",
    "n_diseases_requested": 83,
    "n_diseases_resolved": 65,
    "n_diseases_skipped": 18,
    "resolve_rate": 0.7831,
    "disease_filter": [
      "oncology",
      "cardiovascular",
      "metabolic",
      "neurological",
      "autoimmune",
      "respiratory",
      "rare"
    ],
    "n_drugs": 3002,
    "top_n": 50,
    "global_auc_roc": 0.6736,
    "global_auc_pr": 0.0148,
    "hit_at_50": 0.1783,
    "mrr": 0.0347,
    "skipped_diseases": [
      "Acute Moraxella catarrhalis bronchitis",
      "Acute exacerbation of chronic bronchitis",
      "Acute exacerbation of chronic congestive heart failure",
      "Acute infective exacerbation of chronic obstructive airways disease",
      "Adult growth hormone deficiency",
      "Alcohol withdrawal syndrome",
      "Amyloid Neuropathies, Familial",
      "Anaplastic lymphoma kinase fusion oncogene positive non-small cell lung cancer",
      "Angina Pectoris, Variant",
      "Arterial embolus and thrombosis",
      "Arthritis, Psoriatic",
      "Asthma night-time symptoms",
      "Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome",
      "Atherosclerotic occlusive disease",
      "Beh\u00e7et's disease affecting oral mucosa",
      "Biotin deficiency disease",
      "Bipolar affective disorder, current episode manic",
      "Bipolar disorder in remission"
    ],
    "lowest_auc_diseases": [
      {
        "disease": "Adenosine deaminase deficiency",
        "resolved_as": "adenosine deaminase deficiency",
        "n_positives": 2,
        "n_candidates": 3002,
        "auc_roc": 0.239,
        "auc_pr": 0.0004
      },
      {
        "disease": "Acute lymphoblastic leukemia - category",
        "resolved_as": "acute lymphoblastic leukemia - category",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": 0.2393,
        "auc_pr": 0.0002
      },
      {
        "disease": "Acute myelomonocytic leukemia",
        "resolved_as": "acute myelomonocytic leukemia",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": 0.2393,
        "auc_pr": 0.0002
      },
      {
        "disease": "Acute pulmonary edema",
        "resolved_as": "acute pulmonary edema",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": 0.4392,
        "auc_pr": 0.0006
      },
      {
        "disease": "Amyloid Neuropathies",
        "resolved_as": "amyloid neuropathies",
        "n_positives": 2,
        "n_candidates": 3002,
        "auc_roc": 0.4665,
        "auc_pr": 0.0006
      }
    ],
    "highest_auc_diseases": [
      {
        "disease": "Acquired partial lipodystrophy",
        "resolved_as": "acquired partial lipodystrophy",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": 1.0,
        "auc_pr": 1.0
      },
      {
        "disease": "Anaplastic large T-cell systemic malignant lymphoma",
        "resolved_as": "anaplastic large t-cell systemic malignant lymphoma",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": 0.9953,
        "auc_pr": 0.0333
      },
      {
        "disease": "Acquired generalized lipodystrophy",
        "resolved_as": "acquired generalized lipodystrophy",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": 0.9833,
        "auc_pr": 0.0098
      },
      {
        "disease": "Anaplastic lymphoma kinase positive anaplastic large cell lymphoma",
        "resolved_as": "anaplastic lymphoma kinase positive anaplastic large cell lymphoma",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": 0.9517,
        "auc_pr": 0.0034
      },
      {
        "disease": "Autistic Disorder",
        "resolved_as": "autistic disorder",
        "n_positives": 2,
        "n_candidates": 3002,
        "auc_roc": 0.9239,
        "auc_pr": 0.0097
      }
    ],
    "null_auc_diseases": [
      {
        "disease": "Adult T-Cell Lymphoma/Leukemia",
        "resolved_as": "adult t-cell lymphoma/leukemia",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": null,
        "auc_pr": null
      },
      {
        "disease": "Anxiety Disorders",
        "resolved_as": "anxiety disorders",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": null,
        "auc_pr": null
      },
      {
        "disease": "Arthritis",
        "resolved_as": "arthritis",
        "n_positives": 2,
        "n_candidates": 3002,
        "auc_roc": null,
        "auc_pr": null
      },
      {
        "disease": "B-Cell Lymphomas",
        "resolved_as": "b-cell lymphomas",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": null,
        "auc_pr": null
      },
      {
        "disease": "Biliary Tract Cancer",
        "resolved_as": "biliary tract cancer",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": null,
        "auc_pr": null
      },
      {
        "disease": "Blastic plasmacytoid dendritic cell neoplasm",
        "resolved_as": "blastic plasmacytoid dendritic cell neoplasm",
        "n_positives": 1,
        "n_candidates": 3002,
        "auc_roc": null,
        "auc_pr": null
      }
    ]
  },
  "prospective_predictions": {
    "metadata": {
      "run_timestamp_utc": "2026-02-21T19:18:27.939756+00:00",
      "elapsed_seconds": 15.64,
      "n_diseases_analyzed": 1,
      "n_total_predictions": 5,
      "top_n_per_disease": 5,
      "disclaimer": "All predictions are HYPOTHESES generated by a computational algorithm. They have not been experimentally validated and are not clinical recommendations. Experimental validation is required before any clinical application."
    },
    "paper_table": [
      {
        "Disease": "primary biliary cholangitis",
        "Drug": "RALOXIFENE HYDROCHLORIDE",
        "Score": 0.4778,
        "Confidence": "high",
        "Novelty": "HIGH",
        "Shared genes (n)": 6,
        "Key genes": "NR1H4, NR3C1, PPARD",
        "Key pathways": "Glucose metabolism, PPAR signaling"
      },
      {
        "Disease": "primary biliary cholangitis",
        "Drug": "FENOFIBRIC ACID",
        "Score": 0.4165,
        "Confidence": "high",
        "Novelty": "HIGH",
        "Shared genes (n)": 3,
        "Key genes": "PPARA, PPARD, PPARG",
        "Key pathways": "Glucose metabolism, PPAR signaling"
      },
      {
        "Disease": "primary biliary cholangitis",
        "Drug": "PHENOLPHTHALEIN",
        "Score": 0.4151,
        "Confidence": "high",
        "Novelty": "HIGH",
        "Shared genes (n)": 3,
        "Key genes": "NR1H4, NR3C1, PPARG",
        "Key pathways": "Glucose metabolism, PPAR signaling"
      },
      {
        "Disease": "primary biliary cholangitis",
        "Drug": "SULFASALAZINE",
        "Score": 0.4134,
        "Confidence": "high",
        "Novelty": "HIGH",
        "Shared genes (n)": 3,
        "Key genes": "DHFR, PPARG, MAPT",
        "Key pathways": "Glucose metabolism, PPAR signaling"
      },
      {
        "Disease": "primary biliary cholangitis",
        "Drug": "ROSIGLITAZONE MALEATE",
        "Score": 0.3907,
        "Confidence": "medium",
        "Novelty": "HIGH",
        "Shared genes (n)": 2,
        "Key genes": "PPARG, PPARD",
        "Key pathways": "Glucose metabolism, PPAR signaling"
      }
    ],
    "paper_methods_blurb": "To demonstrate prospective utility beyond retrospective validation, we applied the algorithm to 1 diseases not included in the validation set. For each disease, we report the top-ranked candidates with mechanistic rationale and supporting gene-pathway evidence (Table X). Novelty was assessed as the PubMed co-occurrence literature score: scores < 0.05 indicate few published reports (HIGH novelty). These predictions represent testable hypotheses and are not clinical recommendations.",
    "top_predictions": [
      {
        "drug_name": "RALOXIFENE HYDROCHLORIDE",
        "disease_name": "primary biliary cholangitis",
        "composite_score": 0.4778,
        "confidence": "high",
        "novelty": "HIGH",
        "literature_score": 0.0,
        "shared_genes": [
          "NR1H4",
          "NR3C1",
          "PPARD",
          "MAPT",
          "ATXN2",
          "PPARG"
        ],
        "n_shared_genes": 6,
        "shared_pathways": [
          "Glucose metabolism",
          "PPAR signaling"
        ],
        "n_shared_pathways": 2,
        "drug_mechanism": "",
        "gene_score": 0.084,
        "pathway_score": 1.0,
        "mechanistic_rationale": "RALOXIFENE HYDROCHLORIDE targets NR1H4, NR3C1, PPARD, MAPT (and 2 more genes). These genes are among the top 104 OpenTargets-associated genes for primary biliary cholangitis. Shared biological pathways include: Glucose metabolism, PPAR signaling. The drug's known mechanism (unknown) is mechanistically compatible with the disease biology described in the disease rationale.",
        "testability": "This prediction could be tested in: (1) In vitro: primary biliary cholangitis-relevant cell lines or patient-derived cells treated with RALOXIFENE HYDROCHLORIDE at therapeutic concentrations. (2) In vivo: established animal models of primary biliary cholangitis if available. (3) Epidemiologically: retrospective cohort analysis of patients on RALOXIFENE HYDROCHLORIDE who develop or are diagnosed with primary biliary cholangitis.",
        "disease_rationale": "User-specified disease for prospective analysis.",
        "disclaimer": "HYPOTHESIS ONLY. This is a computational prediction and has not been experimentally validated. It is not a clinical recommendation. Experimental validation is required before any clinical application.",
        "paper_text": "**RALOXIFENE HYDROCHLORIDE for primary biliary cholangitis** (score=0.478, confidence=high): RALOXIFENE HYDROCHLORIDE targets 6 genes associated with primary biliary cholangitis (including NR1H4, NR3C1, PPARD), sharing 2 biological pathways. The drug's mechanism (unknown) suggests plausible therapeutic relevance. Literature co-occurrence score = 0.000 (novelty: HIGH). Experimental validation is warranted."
      },
      {
        "drug_name": "FENOFIBRIC ACID",
        "disease_name": "primary biliary cholangitis",
        "composite_score": 0.4165,
        "confidence": "high",
        "novelty": "HIGH",
        "literature_score": 0.0,
        "shared_genes": [
          "PPARA",
          "PPARD",
          "PPARG"
        ],
        "n_shared_genes": 3,
        "shared_pathways": [
          "Glucose metabolism",
          "PPAR signaling"
        ],
        "n_shared_pathways": 2,
        "drug_mechanism": "",
        "gene_score": 0.0367,
        "pathway_score": 1.0,
        "mechanistic_rationale": "FENOFIBRIC ACID targets PPARA, PPARD, PPARG (). These genes are among the top 104 OpenTargets-associated genes for primary biliary cholangitis. Shared biological pathways include: Glucose metabolism, PPAR signaling. The drug's known mechanism (unknown) is mechanistically compatible with the disease biology described in the disease rationale.",
        "testability": "This prediction could be tested in: (1) In vitro: primary biliary cholangitis-relevant cell lines or patient-derived cells treated with FENOFIBRIC ACID at therapeutic concentrations. (2) In vivo: established animal models of primary biliary cholangitis if available. (3) Epidemiologically: retrospective cohort analysis of patients on FENOFIBRIC ACID who develop or are diagnosed with primary biliary cholangitis.",
        "disease_rationale": "User-specified disease for prospective analysis.",
        "disclaimer": "HYPOTHESIS ONLY. This is a computational prediction and has not been experimentally validated. It is not a clinical recommendation. Experimental validation is required before any clinical application.",
        "paper_text": "**FENOFIBRIC ACID for primary biliary cholangitis** (score=0.417, confidence=high): FENOFIBRIC ACID targets 3 genes associated with primary biliary cholangitis (including PPARA, PPARD, PPARG), sharing 2 biological pathways. The drug's mechanism (unknown) suggests plausible therapeutic relevance. Literature co-occurrence score = 0.000 (novelty: HIGH). Experimental validation is warranted."
      },
      {
        "drug_name": "PHENOLPHTHALEIN",
        "disease_name": "primary biliary cholangitis",
        "composite_score": 0.4151,
        "confidence": "high",
        "novelty": "HIGH",
        "literature_score": 0.0,
        "shared_genes": [
          "NR1H4",
          "NR3C1",
          "PPARG"
        ],
        "n_shared_genes": 3,
        "shared_pathways": [
          "Glucose metabolism",
          "PPAR signaling"
        ],
        "n_shared_pathways": 2,
        "drug_mechanism": "",
        "gene_score": 0.0336,
        "pathway_score": 1.0,
        "mechanistic_rationale": "PHENOLPHTHALEIN targets NR1H4, NR3C1, PPARG (). These genes are among the top 104 OpenTargets-associated genes for primary biliary cholangitis. Shared biological pathways include: Glucose metabolism, PPAR signaling. The drug's known mechanism (unknown) is mechanistically compatible with the disease biology described in the disease rationale.",
        "testability": "This prediction could be tested in: (1) In vitro: primary biliary cholangitis-relevant cell lines or patient-derived cells treated with PHENOLPHTHALEIN at therapeutic concentrations. (2) In vivo: established animal models of primary biliary cholangitis if available. (3) Epidemiologically: retrospective cohort analysis of patients on PHENOLPHTHALEIN who develop or are diagnosed with primary biliary cholangitis.",
        "disease_rationale": "User-specified disease for prospective analysis.",
        "disclaimer": "HYPOTHESIS ONLY. This is a computational prediction and has not been experimentally validated. It is not a clinical recommendation. Experimental validation is required before any clinical application.",
        "paper_text": "**PHENOLPHTHALEIN for primary biliary cholangitis** (score=0.415, confidence=high): PHENOLPHTHALEIN targets 3 genes associated with primary biliary cholangitis (including NR1H4, NR3C1, PPARG), sharing 2 biological pathways. The drug's mechanism (unknown) suggests plausible therapeutic relevance. Literature co-occurrence score = 0.000 (novelty: HIGH). Experimental validation is warranted."
      },
      {
        "drug_name": "SULFASALAZINE",
        "disease_name": "primary biliary cholangitis",
        "composite_score": 0.4134,
        "confidence": "high",
        "novelty": "HIGH",
        "literature_score": 0.0,
        "shared_genes": [
          "DHFR",
          "PPARG",
          "MAPT"
        ],
        "n_shared_genes": 3,
        "shared_pathways": [
          "Glucose metabolism",
          "PPAR signaling"
        ],
        "n_shared_pathways": 2,
        "drug_mechanism": "",
        "gene_score": 0.0297,
        "pathway_score": 1.0,
        "mechanistic_rationale": "SULFASALAZINE targets DHFR, PPARG, MAPT (). These genes are among the top 104 OpenTargets-associated genes for primary biliary cholangitis. Shared biological pathways include: Glucose metabolism, PPAR signaling. The drug's known mechanism (unknown) is mechanistically compatible with the disease biology described in the disease rationale.",
        "testability": "This prediction could be tested in: (1) In vitro: primary biliary cholangitis-relevant cell lines or patient-derived cells treated with SULFASALAZINE at therapeutic concentrations. (2) In vivo: established animal models of primary biliary cholangitis if available. (3) Epidemiologically: retrospective cohort analysis of patients on SULFASALAZINE who develop or are diagnosed with primary biliary cholangitis.",
        "disease_rationale": "User-specified disease for prospective analysis.",
        "disclaimer": "HYPOTHESIS ONLY. This is a computational prediction and has not been experimentally validated. It is not a clinical recommendation. Experimental validation is required before any clinical application.",
        "paper_text": "**SULFASALAZINE for primary biliary cholangitis** (score=0.413, confidence=high): SULFASALAZINE targets 3 genes associated with primary biliary cholangitis (including DHFR, PPARG, MAPT), sharing 2 biological pathways. The drug's mechanism (unknown) suggests plausible therapeutic relevance. Literature co-occurrence score = 0.000 (novelty: HIGH). Experimental validation is warranted."
      },
      {
        "drug_name": "ROSIGLITAZONE MALEATE",
        "disease_name": "primary biliary cholangitis",
        "composite_score": 0.3907,
        "confidence": "medium",
        "novelty": "HIGH",
        "literature_score": 0.0,
        "shared_genes": [
          "PPARG",
          "PPARD"
        ],
        "n_shared_genes": 2,
        "shared_pathways": [
          "Glucose metabolism",
          "PPAR signaling"
        ],
        "n_shared_pathways": 2,
        "drug_mechanism": "",
        "gene_score": 0.0238,
        "pathway_score": 1.0,
        "mechanistic_rationale": "ROSIGLITAZONE MALEATE targets PPARG, PPARD (). These genes are among the top 104 OpenTargets-associated genes for primary biliary cholangitis. Shared biological pathways include: Glucose metabolism, PPAR signaling. The drug's known mechanism (unknown) is mechanistically compatible with the disease biology described in the disease rationale.",
        "testability": "This prediction could be tested in: (1) In vitro: primary biliary cholangitis-relevant cell lines or patient-derived cells treated with ROSIGLITAZONE MALEATE at therapeutic concentrations. (2) In vivo: established animal models of primary biliary cholangitis if available. (3) Epidemiologically: retrospective cohort analysis of patients on ROSIGLITAZONE MALEATE who develop or are diagnosed with primary biliary cholangitis.",
        "disease_rationale": "User-specified disease for prospective analysis.",
        "disclaimer": "HYPOTHESIS ONLY. This is a computational prediction and has not been experimentally validated. It is not a clinical recommendation. Experimental validation is required before any clinical application.",
        "paper_text": "**ROSIGLITAZONE MALEATE for primary biliary cholangitis** (score=0.391, confidence=medium): ROSIGLITAZONE MALEATE targets 2 genes associated with primary biliary cholangitis (including PPARG, PPARD), sharing 2 biological pathways. The drug's mechanism (unknown) suggests plausible therapeutic relevance. Literature co-occurrence score = 0.000 (novelty: HIGH). Experimental validation is warranted."
      }
    ]
  },
  "summary_for_paper": {
    "curated_validation": {
      "sensitivity": 0.96,
      "specificity": 0.9667,
      "precision": 0.96,
      "f1": 0.96,
      "tp": 24,
      "fn": 1,
      "tn": 29,
      "fp": 1
    },
    "bootstrap_95ci": {
      "sensitivity": {
        "point": 0.96,
        "lower": 0.88,
        "upper": 1.0
      },
      "specificity": {
        "point": 0.9667,
        "lower": 0.9,
        "upper": 1.0
      },
      "precision": {
        "point": 0.96,
        "lower": 0.8846,
        "upper": 1.0
      },
      "f1": {
        "point": 0.96,
        "lower": 0.898,
        "upper": 1.0
      }
    },
    "repodb": {
      "auc_roc": 0.6736,
      "auc_pr": 0.0148,
      "hit_at_50": 0.1783,
      "mrr": 0.0347,
      "n_diseases": 65
    },
    "calibration": {
      "platt_A": -0.0266,
      "platt_B": -0.1076,
      "ece": 0.0188
    },
    "baseline_f1_deltas": {
      "jaccard": {
        "main_f1": 0.96,
        "baseline_f1": 0.7826,
        "f1_delta": 0.1774,
        "main_better": true
      },
      "gene_count": {
        "main_f1": 0.96,
        "baseline_f1": 0.8085,
        "f1_delta": 0.1515,
        "main_better": true
      },
      "cosine": {
        "main_f1": 0.96,
        "baseline_f1": 0.8182,
        "f1_delta": 0.1418,
        "main_better": true
      }
    },
    "sensitivity_analysis_stable": true
  }
}